High-dose nabiximols for cannabis use disorder did not cause concerning changes in lab markers

Sub-chronic exposure to nabiximols at doses higher than typically used for MS treatment did not produce clinically significant changes in biological markers. Laboratory values for liver function, metabolic parameters, and other clinical measures remained stable.

Secondary analysis of biological marker data from a clinical trial using nabiximols for cannabis use disorder. Monitored liver function, metabolic markers, and other clinical laboratory values during treatment with higher-than-standard doses.

Treating cannabis use disorder with nabiximols likely requires higher doses than MS treatment due to tolerance. Demonstrating safety at these elevated doses is essential before larger efficacy trials can proceed.

Nabiximols (Sativex) is already approved for MS in many countries. Repurposing it for CUD at higher doses requires separate safety validation. This study helps clear that safety hurdle for future efficacy trials.

Secondary analysis from a trial likely with a small sample. Short treatment duration (sub-chronic). Does not address long-term safety. Biological markers are only one aspect of safety (does not capture subjective side effects or behavioral outcomes). Population with CUD may tolerate cannabinoids differently than MS patients.